[1] Ludwig J, Viggiano T R, McGill D B, et al. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc, 1980, 55(7): 434-438.
[2] Yang A, Zhu X, Zhang L, et al. Transitioning from NAFLD to MAFLD and MASLD: consistent prevalence and risk factors in a Chinese cohort[J]. J Hepatol, 2024, 80(4): e154-e155.
[3] Song S J, Lai J C, Wong G L, et al. Can we use old NAFLD data under the new MASLD definition?[J]. J Hepatol, 2024, 80(2): e54-e56.
[4] Wang X, Wu S, Yuan X, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study[J]. J Clin Endocrinol Metab, 2022, 107(2): e745-e755.
[5] Chen L, Tao X, Zeng M, et al. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD[J]. J Hepatol, 2024, 80(2): e64-e66.
[6] Ayada I, van Kleef L A, Alferink L J M, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups[J]. Liver Int, 2022, 42(2): 277-287.
[7] Perazzo H, Pacheco A G, Griep R H. Changing from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort[J]. J Hepatol, 2024, 80(2): e72-e74.
[8] Nakano M, Kawaguchi M, Kawaguchi T. Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia[J]. J Hepatol, 2024, 80(4): e155-e157.
[9] 刘云霄, 郭峰, 牛丽娜, 等. 从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病——基于临床特征差异分析[J]. 中华肝脏病杂志, 2024, 32(4): 346-353.
[10] Yu C, Wang M, Zheng S, et al. Comparing the diagnostic criteria of MAFLD and NAFLD in the Chinese population: a population-based prospective cohort study[J]. J Clin Transl Hepatol, 2022, 10(1): 6-16.
[11] He L, Zheng W, Qiu K, et al. Changing from NAFLD to MASLD: the new definition can more accurately identify individuals at higher risk for diabetes[J]. J Hepatol, 2024, 80(2): e85-e87.
[12] Kim D, Konyn P, Sandhu K K, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States[J]. J Hepatol, 2021, 75(6): 1284-1291.
[13] Song R, Li Z, Zhang Y, et al. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults[J]. Liver Int, 2024, 44(4): 1051-1060.
[14] Kim K S, Hong S, Ahn H Y, et al. Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study[J]. Diabetes Metab J, 2023, 47(2): 220-231.
[15] Moon J H, Kim W, Koo B K, et al. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease[J]. Gut Liver, 2022, 16(3): 433-442.
[16] Branković M, Dukić M, Gmizić T, et al. New therapeutic approaches for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and increased cardiovascular risk[J]. Diagnostics (Basel), 2024, 14(2): 229.
[17] EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease[J]. Obes Facts, 2016, 9(2): 65-90.
[18] Cleveland E R, Ning H, Vos M B, et al. Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample: the CARDIA study[J]. J Gen Intern Med, 2019, 34(12): 2772-2778.
[19] Wieland A C, Mettler P, McDermott M T, et al. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk[J]. J Clin Gastroenterol, 2015, 49(1): e6-e10.
[20] Rojas Á, Lara-Romero C, Muáoz-Hernández R, et al. Emerging pharmacological treatment options for MAFLD[J]. Ther Adv Endocrinol Metab, 2022, 13: 20420188221142452. |
